Uromigos-Bladder Cancer

The UromigosThe Uromigos | January 31, 2023
Petros Grivas, MD, PhD, joins The Uromigos to discuss the use of antibody drug conjugates in bladder cancer.
Listen Now
The UromigosThe Uromigos | January 23, 2023
A summary of the prostate and bladder cancer session of the Conversations & Trending Topics in GU Cancers conference.
The UromigosThe Uromigos | January 9, 2023
Sam Chang, MD, MBA, joins The Uromigos to discuss the results of IL-15RαFc superagonist N-803 for papillary NMIBC.
The UromigosThe Uromigos | December 20, 2022
Is cisplatin any different from carboplatin in advanced bladder cancer? The Uromigos debate the topic with Matt Galsky, MD.
The UromigosThe Uromigos | November 28, 2022
Dr. Andrea Necchi describes his recent phase 2 study on the use of neoadjuvant pembrolizumab and nab-paclitaxel for MIBC.
The UromigosThe Uromigos | October 25, 2022
The Uromigos chat with Cora Sternberg on her paper on FGFR inhibition in advanced urothelial cancer.
The UromigosThe Uromigos | August 22, 2022
John Kelly summarizes a recent paper published in JAMA that describes the benefits of robotic surgery versus open cystectomy.
The Uromigos | August 15, 2022
Cora Sternberg, MD, discusses her career that has spanned multiple continents.
The UromigosThe Uromigos | May 9, 2022
Syed Hussain and Sam Funt describe their studies on this topic.
The UromigosThe Uromigos | March 14, 2022
Matt Galsky and Tom Powles take the FDA and EMA approach respectively concerning adjuvant nivolumab for bladder cancer.
The UromigosThe Uromigos | March 7, 2022
Cisplatin-based combination chemotherapy is considered standard of care in mUC, but many patients are deemed ineligible.
The UromigosThe Uromigos | February 18, 2022
Dr. Jonathan Rosenberg describes the results of this positive randomized phase 2 trial.
The UromigosThe Uromigos | January 31, 2022
Dr. Joaquim Bellmunt gives an overview of the updated ESMO guidelines on bladder cancer.
The UromigosThe Uromigos | December 13, 2021
Jonathan Rosenberg discusses what happened in the world of bladder cancer during 2021 and what to look out for in 2022.
The UromigosThe Uromigos | December 2, 2021
Dr. Arjun Balar discusses bladder cancer, clinical trials involving pembrolizumab, and his career transition.
The UromigosThe Uromigos | September 17, 2021
Dr. Sarmad Sadeghi discusses exciting data about a novel compound in urothelial cancer with Brian and Tom.
The UromigosThe Uromigos | September 17, 2021
Dr. Jonathan Rosenberg gives an overview of the NORSE Study.
The UromigosThe Uromigos | August 23, 2021
Dr. Dean Bajorin discusses developments in bladder and collaboration in testis cancer.
The UromigosThe Uromigos | July 23, 2021
Dr. Ashish Kamat walks through ongoing issues around surgery in urothelial cancer at EAU 2021.
The UromigosThe Uromigos | June 7, 2021
Join the debate around pembrolizumab monotherapy in initial treatment of cisplatin-ineligible metastatic urothelial cancer.
Advertisement
Advertisement